Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Forms New Clinical Research Hub In Singapore To Accelerate Progress In Personalized Medicine

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Roche announced Jan. 28 a major strategic alliance with Singapore's leading scientific and medical institutions to establish a new translational research hub in Singapore

You may also be interested in...



Singapore Gains Momentum As Major R&D, Manufacturing Hub; Sees Double-digit Pharma Sector Growth

SHANGHAI - Output of Singapore's biomedical manufacturing cluster increased 14.8 percent last year, according to Singapore's Economic Development Board. Within the cluster, the pharmaceuticals segment grew 15.6 percent with higher levels of production of active pharmaceutical ingredients. Output of the medical technology segment edged up 0.8 percent to meet export orders for surgical and medical instruments

Singapore Gains Momentum As Major R&D, Manufacturing Hub; Sees Double-digit Pharma Sector Growth

SHANGHAI - Output of Singapore's biomedical manufacturing cluster increased 14.8 percent last year, according to Singapore's Economic Development Board. Within the cluster, the pharmaceuticals segment grew 15.6 percent with higher levels of production of active pharmaceutical ingredients. Output of the medical technology segment edged up 0.8 percent to meet export orders for surgical and medical instruments

Investing In China: Views From Windhover's PharmAsia Summit

It's common wisdom within the halls of Big Pharma to look East--especially to China--for future revenue growth as increasing regulatory oversight and reimbursement hurdles in the U.S. and Europe create commercial challenges

Related Content

UsernamePublicRestriction

Register

SC073139

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel